Page last updated: 2024-11-12

ptc 124

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11219835
CHEMBL ID256997
CHEBI ID94805
SCHEMBL ID60614
MeSH IDM0505218

Synonyms (71)

Synonym
3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
HY-14832
BB 0261439
ptc124 ,
ataluren ,
ptc-124
translarna
CHEMBL256997
NCGC00168759-04
NCGC00168759-02
AKOS005146455
775304-57-9
D09323
translarna (tn)
ataluren (usan/inn)
FT-0651455
NCGC00168759
A15804
ptc124;3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid;ptc-124
EX-3387
3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid
ataluren [usan:inn]
k16ame9i3v ,
benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-
unii-k16ame9i3v
ptc 124
cas-775304-57-9
dtxcid3026776
tox21_112631
dtxsid5046776 ,
BCPP000097
ptc124,ataluren
CS-0503
S6003
gtpl7341
BRD-K94830329-001-01-4
ataluren [mi]
ataluren [who-dd]
ataluren [inn]
DB05016
ataluren [usan]
SCHEMBL60614
smr004702931
MLS006011160
ataluren (ptc124)
AM808091
benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-
NCGC00168759-05
tox21_112631_1
OOUGLTULBSNHNF-UHFFFAOYSA-N
3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid
ptc124 (ataluren)
AC-28390
mfcd09864996
EX-A385
GS-3946
CHEBI:94805
HMS3656H20
ataluren; ptc124
NCGC00168759-10
SW219696-1
ataluren(ptc124)
BCP01756
Q753330
SB16685
CCG-267286
AU-004/43508117
JBF ,
EN300-7386374
bdbm50582214

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Ataluren had a favorable safety profile; most treatment-emergent adverse events were mild or moderate and unrelated to ataluren."( Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis.
Buccella, F; de Resende, MBD; Desguerre, I; Gordish-Dressman, H; Henricson, EK; Johnson, S; Kirschner, J; Kristensen, A; McDonald, CM; Mercuri, E; Morgenroth, LP; Muntoni, F; Osorio, AN; Trifillis, P; Tulinius, M; Werner, C, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options."( PTC124 targets genetic disorders caused by nonsense mutations.
Almstead, NG; Babiak, J; Barton, ER; Branstrom, AA; Campbell, JA; Chen, G; Colacino, JM; Conn, MM; Corson, D; Feng, H; Friesen, WJ; He, F; Hedrick, J; Hirawat, S; Hwang, S; Jacobson, A; Jones, S; Ju, WD; Karp, G; Kawana, M; Khan, A; Miller, LL; Mollin, A; Moon, YC; Northcutt, VJ; Patel, M; Paushkin, S; Peltz, SW; Ren, H; Risher, N; Spatrick, P; Sweeney, HL; Takasugi, J; Tomizawa, Y; Trifillis, P; Trotta, CR; Turpoff, AA; Weetall, M; Welch, EM; Wilde, RG; Yeh, S; Zhuo, J, 2007
)
0.34
" PTC124 is an orally bioavailable compound that promotes readthrough of premature translation termination codons, suggesting that it may have the potential to treat genetic diseases caused by nonsense mutations."( PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Bedwell, DM; Du, M; Hirawat, S; Liu, X; Peltz, SW; Welch, EM, 2008
)
0.35
" PTC124 is an orally bioavailable small molecule that is designed to induce ribosomes to selectively read through premature stop codons during mRNA translation, to produce functional CFTR."( Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Armoni, S; Aviram, M; Blau, H; Cohen, M; Elfring, GL; Hirawat, S; Kerem, B; Kerem, E; Miller, LL; Nissim-Rafinia, M; Northcutt, VJ; Rivlin, J; Shoseyov, D; Wilschanski, M; Yaakov, Y, 2008
)
0.35
" It exhibits oral bioavailability and limited toxicity in human trials."( Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
Aldred, MA; Drake, KM; Dunmore, BJ; McNelly, LN; Morrell, NW, 2013
)
0.39
" Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations."( New and emerging targeted therapies for cystic fibrosis.
Quon, BS; Rowe, SM, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" No drug accumulation with repeated dosing was apparent."( Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.
Almstead, NG; Elfring, GL; Hirawat, S; Hwang, S; Ju, W; Leonard, EM; Miller, LL; Northcutt, VJ; Paushkin, S; Peltz, SW; Welch, EM, 2007
)
0.34
" Several of the published studies in cystic fibrosis have reported improvements in cystic fibrosis transmembrane conductance regulator (CFTR) biomarkers during short-term evaluation, including topical and systemic aminoglycoside treatment, and oral dosing with PTC124."( Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Clancy, JP; Rowe, SM, 2009
)
0.35
" Ataluren requires 3 times a day dosing and is currently in a Phase 3 placebo-controlled study."( Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit, RS,
)
0.13
" Nonsense read-through drugs are a potential form of treatment for PKU, although the high dosage of aminoglycosides used is not appropriate in a clinical setting."( In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.
Christodoulou, J; Ho, G; Reichardt, J, 2013
)
0.39
" The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg."( Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
Barth, J; Bönnemann, C; Elfring, G; Finkel, RS; Flanigan, KM; Northcutt, VJ; Peltz, SW; Reha, A; Sampson, J; Sweeney, HL; Wong, B, 2013
)
0.39
" Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye."( Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.
Gregory-Evans, CY; Gregory-Evans, K; Metcalfe, AL; Wang, X; Wasan, KM; Zhao, J, 2014
)
0.4
"Gln2598Stop), who started the treatment with Ataluren at a dosage of 2,250 mg/die, reporting a prompt subjective improvement in muscle strength."( Therapeutic approach with Ataluren in Duchenne symptomatic carriers with nonsense mutations in dystrophin gene. Results of a 9-month follow-up in a case report.
D'Ambrosio, P; Nigro, V; Orsini, C; Politano, L, 2018
)
0.48
"Gln3601X in exon 76, who was early treated with Ataluren at a dosage of 40 mg/kg/die, and presented a rapid improvement in both muscle strength and cognitive and social skills."( Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy.
Bertella, M; Bitetti, I; Manna, MR; Mautone, C; Varone, A, 2021
)
0.62
" Ataluren has a bell-shaped dose-response curve and a narrow effective range."( Ataluren suppresses a premature termination codon in an MPS I-H mouse.
Du, M; Gunn, G; Keeling, KM; Siddiqui, A; Wang, D; Weetall, M; Xue, X, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
oxadiazole
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency0.00790.007215.758889.3584AID1224835; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00270.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency14.25820.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency14.25820.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency0.21270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency3.96350.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency14.13640.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.00530.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.70900.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency19.49600.001310.157742.8575AID1259252; AID1259253; AID1259255
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.21230.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency7.56240.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.22950.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency0.00600.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.80270.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080
GVesicular stomatitis virusPotency1.54870.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.54870.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency5.30760.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency18.83220.001019.414170.9645AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency0.01600.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00670.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.01780.10009.191631.6228AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.29470.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency0.41370.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency12.95930.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.70790.00798.23321,122.0200AID2546
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency8.41270.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency1.54870.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.54870.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency8.41270.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.54870.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.02570.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.02370.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.54870.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Flavin reductase (NADPH)Homo sapiens (human)Kd0.19980.07000.79681.7100AID1815675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (188)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
megakaryocyte differentiationFlavin reductase (NADPH)Homo sapiens (human)
heme catabolic processFlavin reductase (NADPH)Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayFlavin reductase (NADPH)Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (63)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
biliverdin reductase (NAD(P)H) activityFlavin reductase (NADPH)Homo sapiens (human)
protein bindingFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NAD(P)H) activityFlavin reductase (NADPH)Homo sapiens (human)
peptidyl-cysteine S-nitrosylase activityFlavin reductase (NADPH)Homo sapiens (human)
riboflavin reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NADH) activityFlavin reductase (NADPH)Homo sapiens (human)
biliberdin reductase NAD+ activityFlavin reductase (NADPH)Homo sapiens (human)
biliverdin reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmFlavin reductase (NADPH)Homo sapiens (human)
nucleoplasmFlavin reductase (NADPH)Homo sapiens (human)
cytosolFlavin reductase (NADPH)Homo sapiens (human)
plasma membraneFlavin reductase (NADPH)Homo sapiens (human)
intracellular membrane-bounded organelleFlavin reductase (NADPH)Homo sapiens (human)
extracellular exosomeFlavin reductase (NADPH)Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (124)

Assay IDTitleYearJournalArticle
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID330978Reduction in serum creatinine levels in orally and ip dosed mdx mouse Extensor digitorum longus muscle after 2 weeks2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331020Increase in N64758 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1588390Inhibition of firefly luciferase activity expressed in Hela cells assessed as reduction in luminescence at 10 uM after 48 hrs by Bright-glo luciferase assay2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation.
AID1586839Induction of read through activity at cricket paralysis virus-internal ribosome entry site premature termination codon UGA assessed as ratio of plateau octapeptide to FKVRQ-tRNAGln measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-Met-tRN2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID330984Antimicrobial activity against Staphylococcus aureus 292132007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330979Increase in level of gamma sarcoplycan in mdx mouse muscle2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331001Decrease in LOC255798 mRNA level in human HEK293 cells at 5 after 48 hrs uM by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331013Induction of readthrough of normal termination codon of beta-2 microglobulin mRNA in human pooled PBMC cells at 200 mg/kg, po by Western blotting2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330989Drug level in Sprague-Dawley female rat plasma at 300 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1327948Binding affinity to CFTR mRNA UGA mutant in human IB3-1 cells carrying W1282X mutation in CFTR gene assessed as increase in CFTR expression measured after 24 to 72 hrs by Western blot analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.
AID331014Decrease in AW4749 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1815672Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID330988Drug level in Sprague-Dawley male rat plasma at 300 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331024Protection against contraction-induced injury in ip dosed mouse extensor digitorum longus muscle assessed as prevention of loss of force after 14 weeks2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330995Drug level in dog plasma at 1500 mg/kg after 11 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330983Antimicrobial activity against Pseudomonas aeruginosa 278532007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330985Antimicrobial activity against Staphylococcus epidermis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330999Decrease in MRPL41mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1655402Cytotoxicity against rat FRT cells at 12 uM after 24 to 72 hrs by trypan blue staining based assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).
AID331018Increase in BG054539 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331004Decrease in HRASLS2 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1588377Effect on non-miRNA pathway in human HeLa cells harboring psi-check empty vector assessed as increase in luminescence at 10 uM after 48 hrs by dual luciferase assay relative to control2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation.
AID331021Induction of ribosomal readthrough of premature nonsense codon UAG LUC190 in human HEK293 cells after 16 hrs by luciferase assay2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330977Ratio of dystrophin to myosine at 5 ug/ml in DMD human myotubes relative to non DMD myotubes2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330981Increase in LUC mRNA level in human HEK293 cells by RT-PCR2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331005Increase in LOC220980 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1815675Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID330992Drug level in Sprague-Dawley male rat plasma at 1800 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331006Increase in CTRC mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1327945Binding affinity to Photinus pyralis luciferase mRNA harboring the UGA premature stop codon expressed in human HeLa cells assessed as suppression of nonsense mutations by read-through of premature stop codon at 12 uM measured after 24 hrs by luminescence 2016European journal of medicinal chemistry, Oct-21, Volume: 122Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.
AID330975Suppression of multiple proximal nonsense codon in human HEK293 cells2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680122Induction of read through activity at CFTR gene premature termination codon UGA transfected in human IB3-1 harboring CFTR deltaF508/W1282X cells assessed as CFTR localization at cellular membrane at 12 uM measured after 24 hrs by DAPI staining based fluor2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID331016Increase in AI075924 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1815673Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in entropy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID330993Drug level in Sprague-Dawley female rat plasma at 1800 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1586840Induction of read through activity at cricket paralysis virus-internal ribosome entry site codon UGG assessed as increase in octapeptide formation from FKVRQ-tRNAGln at EC50 to 2 times EC50 measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID331022Induction of ribosomal readthrough of premature nonsense codon UGA LUC190 in human HEK293 cells after 16 hrs by luciferase assay2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680113Induction of CFTR channel function restoration in FRT cells assessed as effect on forskolin induced transepithelial CFTR-mediated Cl- current by measuring basal short circuit current at 12 uM measured after 24 hrs by voltage clamp method2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID330974Induction of ribosomal readthrough of premature nonsense codon UAA LUC190 in human HEK293 cells after 16 hrs by luciferase assay2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1728171Metabolic stability in mouse liver microsomes assessed as half life in presence of NADPH by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID1815674Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in gibbs free energy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID331010Ratio of dystrophin to myosine in mdx mouse myotubes at 10 ug/ml relative to wild type C57-mouse2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330987Antimicrobial activity against Enterococcus faecalis 292122007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1327943Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 12 uM measured after 24 to 72 hrs2016European journal of medicinal chemistry, Oct-21, Volume: 122Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.
AID331019Increase in AI668569 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331002Decrease in SLC7A1 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331003Decrease in ZNF206 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331007Increase in INSL3 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1586844Induction of read through activity at cricket paralysis virus-internal ribosome entry site codon UGG assessed as rate constant for octapeptide formation from FKVRQ-tRNAGln at 500 uM preincubated for 30 secs in presence of Typ-tRNA followed by Leu-tRNA and2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID331023Protection against contraction-induced injury in po dosed mouse extensor digitorum longus muscle assessed as prevention of loss of force after 14 weeks2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331008Increase in ORTC1 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1728167Activation of NF-KappaB (unknown origin) expressed in SH-SY5Y cells co-transfected with pNFkappaB-Luc/pEF6 measured after 24 hrs by Bright-Glo luciferase assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID330994Drug level in dog plasma at 500 mg/kg after 11 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330976Induction of ribosomal readthrough of dystrophin mRNA premature nonsense codons in primary muscle cell culture at 17 uM by immunocytometry2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330997Decrease in MECP2 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330996Decrease in LCN8 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680124Induction of read through activity at UGA stop mutation codon (unknown origin) transfected in human HeLa cells assessed as increase in luciferase activity at 12 uM incubated for 24 hrs by steady-glo luciferase reporter gene assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID330982Antimicrobial activity against Escherichia coli BAS8492007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1728168Activation of NF-KappaB (unknown origin) expressed in SH-SY5Y cells co-transfected with pNFkappaB-Luc/pEF6 measured after 24 hrs by Bright-Glo luciferase assay relative to control2021European journal of medicinal chemistry, Jan-15, Volume: 210Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID330998Decrease in CSMD1 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680104Induction of DNA damage in human IMR-90 cells assessed as increase in p53 phosphorylation at Ser15 at 12 uM measured after 72 hrs by DAPI staining based immunofluorescence assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID1141939Agonist activity at AHR in mouse HC11 cells assessed as upregulation of Cyp1a1 gene expression at 10 uM after 48 hrs by RT-PCR analysis relative to control2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor.
AID331017Increase in AI521273 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330986Antimicrobial activity against Enterococcus faecium 496242007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1586845Induction of read through activity at cricket paralysis virus-internal ribosome entry site premature termination codon UGA assessed as rate constant for octapeptide formation from FKVRQ-tRNAGln at 500 uM preincubated for 30 secs in presence of Typ-tRNA fo2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID1655401Induction of read through activity at CFTR gene premature termination codon UGA transfected in human HeLa cells assessed as increase in luciferase activity at 12 uM incubated for 24 hrs by steady-glo luciferase reporter gene assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).
AID331012Increase in HDAC11 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680110Cytotoxicity against human IMR-90 cells assessed as increase in dead cells at 12 uM measured after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID330980Effect on production of dystrophin in mdx mouse muscle by Western blotting2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331011Effect on LUC190 CD40 mRNA assessed as luciferase accumulation in human HEK293 cells by Western blotting2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1728170Metabolic stability in human liver microsomes assessed as half life in presence of NADPH by LC/MS analysis2021European journal of medicinal chemistry, Jan-15, Volume: 210Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID1586838Induction of read through activity at cricket paralysis virus-internal ribosome entry site premature termination codon UGA assessed as increase in octapeptide formation from FKVRQ-tRNAGln measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID330990Drug level in Sprague-Dawley male rat plasma at 600 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331009Increase in XLHSRF1 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330991Drug level in Sprague-Dawley female rat plasma at 600 mg/kg after 14 days2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID330973Aqueous solubility of the compound2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID331000Decrease in ARHGEF12 mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID1680112Cytotoxicity against human IMR-90 cells assessed as increase in dead cells at 12 uM measured after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Nov-05, Volume: 159Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
AID1728176Kinetic solubility of compound at pH 7.4 by shake flask method2021European journal of medicinal chemistry, Jan-15, Volume: 210Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.
AID331015Increase in AA844509 genebank mRNA level in human HEK293 cells at 5 uM after 48 hrs by microarray analysis2007Nature, May-03, Volume: 447, Issue:7140
PTC124 targets genetic disorders caused by nonsense mutations.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (189)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's24 (12.70)29.6817
2010's118 (62.43)24.3611
2020's47 (24.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.55 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index35.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (8.90%)5.53%
Reviews43 (22.51%)6.00%
Case Studies7 (3.66%)4.05%
Observational0 (0.00%)0.25%
Other124 (64.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]